Quick Takeaways
- Deciphera Pharmaceuticals, Inc. financial facts are built from SEC company filings data.
- Latest metrics period on this page: Q1 2024.
- Headline metric: Return On Equity -50%.
Professional SEC-based dashboard for profitability, financial health, and growth with transparent scoring logic. Latest period: Q1 2024.
Facts and ratios are grounded in SEC company facts linked to the latest 10-Q/10-K cycle.
See Original FilingLatest SEC snapshot (2024-05-06) highlights Return On Equity -50.4%, Return On Assets -39.3%, and Operating Margin -118.1%.
Transparent 0-100 scoring model based on profitability, financial health, and growth factors.
44.3/100
Caution Confidence high
-50%
Metric score 0.0/100
-39%
Metric score 0.0/100
Quick Ratio, Debt-to-equity, and Revenues YoY
Return On Equity, Return On Assets, and Operating Margin
Return On Equity
-50%
YoY: -1.4%
Industry median: -43% (n=675)
Return On Assets
-39%
YoY: +0.97%
Industry median: -47% (n=673)
Operating Margin
-118%
YoY: -14%
Industry median: -121% (n=298)
Current Ratio
4.19x
YoY: -26%
Industry median: 3.39x (n=667)
Quick Ratio
1.49x
YoY: -9.1%
Industry median: 1.51x (n=289)
Debt-to-equity
0.31x
YoY: +13%
Industry median: 0.26x (n=530)
Revenues YoY
27%
YoY:
Industry median: 7.3% (n=302)
NetIncomeLoss YoY
-4.8%
YoY:
Industry median: -0.93% (n=641)
| Metric | Latest value | YoY change |
|---|---|---|
| Return On Equity | -50% | -1.4% |
| Return On Assets | -39% | +0.97% |
| Operating Margin | -118% | -14% |
| Metric | Latest value | YoY change |
|---|---|---|
| Current Ratio | 4.19x | -26% |
| Quick Ratio | 1.49x | -9.1% |
| Debt-to-equity | 0.31x | +13% |
| Metric | Latest value | YoY change |
|---|---|---|
| Revenues YoY | 27% | |
| NetIncomeLoss YoY | -4.8% |
| Metric | Latest value | YoY change |
|---|---|---|
| Entity Common Stock, Shares Outstanding | 86,475,972 | +10% |
| Common Stock, Shares, Outstanding | 82,158,670 | +4.6% |
| Common Stock, Value, Issued | $821,000 | +4.6% |
| Weighted Average Number of Shares Outstanding, Basic | 87,388,106 | +5.7% |
| Weighted Average Number of Shares Outstanding, Diluted | 87,388,106 | +5.7% |
This score is transparent and deterministic. We weight profitability, financial health, and growth metrics, then renormalize weights when SEC data is missing.
| Metric | Weight | V1 threshold |
|---|---|---|
| ROIC | 20 | 5% to 20% |
| ROE | 15 | 8% to 25% |
| ROA | 10 | 2% to 10% |
| Operating Margin | 5 | 5% to 25% |
| Current Ratio | 12 | 1.0x to 2.0x |
| Quick Ratio | 8 | 0.8x to 1.5x |
| Debt to Equity | 10 | 0.3x to 2.0x (lower is better) |
| Revenue YoY | 10 | -10% to +20% |
| Net Income YoY | 10 | -10% to +20% |
Metrics are computed with a market-consensus convention designed for cross-portal comparability.